medigraphic.com
ISSN 1870-2821 (Impreso)
Organo Oficial de la Asociación Mexicana de Mastología

2015, Número 1

<< Anterior Siguiente >>

Rev Mex Mastol 2015; 5 (1)


Actualidades del tratamiento del cáncer de mama metastásico HER2-positivo

Matus-Santos JA, Arce-Salinas C, Flores-Díaz D, Reynoso-Noverón N, Villarreal-Garza C, Alvarado-Miranda A, Lara-Medina F, Mohar-Betancourt A

Idioma: Español
Referencias bibliográficas: 36
Paginas: 18-22
Archivo PDF: 201.43 Kb.


RESUMEN

El cáncer de mama HER2-positivo representa el 20% de todos los casos; se caracteriza por poseer una mayor agresividad biológica; sin embargo, desde el advenimiento de las terapias biológicas, el pronóstico y el curso clínico de la enfermedad han cambiado. El objetivo de esta revisión es dar una perspectiva de los tratamientos actuales


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64 (1): 9-29.

  2. Salinas-Martínez AM, Juárez-Ruiz A, Mathiew-Quirós A, Guzmán-De la Garza FJ, Santos-Lartigue A, Escobar-Moreno C. Breast cancer in México: a 10-year trend analysis on incidence and age at diagnosis. Rev Invest Clin. 2014; 66 (3): 210-217.

  3. Chavarri-Guerra Y, Villarreal-Garza C, Liedke PE, Knaul F, Mohar A, Finkelstein DM et al. Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol. 2012; 13 (8): e335-e343.

  4. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360 (8): 790-800.

  5. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011; 117 (16): 3658-3669.

  6. Arce-Salinas C, Lara-Medina FU, Alvarado-Miranda A, Castañeda-Soto N, Bargalló-Rocha E, Ramírez-Uglade MT et al. Evaluation of breast cancer treatment at a tertiary-level institution with popular health insurance in Mexico. Rev Invest Clin. 2012; 64 (1): 9-16.

  7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235 (4785): 177-182.

  8. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998; 16 (4): 1340-1349.

  9. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly MB, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999; 26 (4 Suppl 12): 60-70.

  10. Teemu TJ, Akita RW et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009; 15: 429-440.

  11. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002; 62 (14): 4132-4141.

  12. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2 (2): 127-137.

  13. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6 (4): 443-446.

  14. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006; 94 (2): 259-267.

  15. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998; 58 (13): 2825-2831.

  16. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999; 18 (13): 2241-2251.

  17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344 (11): 783-792.

  18. Von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011; 47: 2273-2281.

  19. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001; 1 (2): 85-94.

  20. Konecny GE, Pegram MD, Venkastesan N, Finn R, Yang G, Rahmeh M et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66 (3): 1630-1639.

  21. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008; 26 (18): 2999-3005.

  22. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355 (26): 2733-2743.

  23. Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di leo A et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA 31. J Clin Oncol. 2015; 33: 1574-1583.

  24. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28: 1124-1130.

  25. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012; 30: 2585-2592.

  26. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004; 5 (4): 317-328.

  27. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009; 69 (24): 9330-9336.

  28. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366 (2): 109-119.

  29. Lewis-Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68 (22): 9280-9290.

  30. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011; 128 (2): 347-356.

  31. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012; 30 (26): 3234-3241.

  32. Ellis PA, Barrios CH, Eiermann W, Toi M, Im YH, Franco-Conte P et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) + pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study. J Clin Oncol. 2015; 33 (suppl; abstr 507).

  33. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367 (19): 1783-1791.

  34. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32 (19): 2078-2099.

  35. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014; 23 (5): 489-502.

  36. Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014; 15 (7): 689-699.




2020     |     www.medigraphic.com